JonesResearch raised the firm’s price target on Spyre Therapeutics (SYRE) to $95 from $64 and keeps a Buy rating on the shares after the company reported the SPY001 monotherapy topline results. The firm increased its probability of success for Spyre’s inflammatory bowel disease programs after the SPY001 readout.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics Raises Capital Through Completed Stock Offering
- 3 Best Trending Stocks, According to Analysts – 4/16/2026
- Spyre Therapeutics 6.5M share Secondary priced at $62.00
- Spyre Therapeutics price target raised to $90 from $65 at Baird
- Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo